NCT04327934

Mechanisms of Hypertension in Women With Polycystic Ovary Syndrome

• Status: Terminated
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 28 (actual)
• Sponsor: Yale University · Academic / Other
• Sex: Female
• Age: 18 Years – 35 Years
• Healthy volunteers: Accepted

Summary

Women with androgen excess polycystic ovary syndrome (AE-PCOS) leads to hypertension.

Detailed description

Our scientific premise is that in AE-PCOS women, the androgen-dominant hormonal milieu causes BP increases via sympathetic activation, vasoconstriction and renal sympathetic nervous system activation. Moreover, this androgen-dominant milieu increases BP via activation of the renin-angiotensin system.

Conditions

• Polycystic Ovary Syndrome
• Hypertension

Interventions

Type	Name	Description
DRUG	GnRH antagonist	GnRH antagonist up to 16 days.
DRUG	GnRH antagonist + MethylTESTOSTERone 5 MG	GnRH antagonist + MethylTESTOSTERone 5 MG up to 5 days.

Timeline

• Start date: 2017-12-01
• Primary completion: 2022-06-30
• Completion: 2022-06-30
• First posted: 2020-03-31
• Last updated: 2024-02-02
• Results posted: 2024-02-02

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study